Open AccessRecent developments in pleurodesis for malignant pleural disease
Author(s) -
Guinde Julien,
Georges Samer,
Bourinet Valerian,
Laroumagne Sophie,
Dutau Herve,
Astoul Philippe
Publication year - 2018
Publication title -
the clinical respiratory journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.789
H-Index - 33
eISSN - 1752-699X
pISSN - 1752-6981
DOI - 10.1111/crj.12958
Subject(s) - medicine , pleurodesis , malignant pleural effusion , thoracentesis , thoracoscopy , intensive care medicine , quality of life (healthcare) , pleural effusion , surgery , nursing
Objective Metastatic pleural effusion (MPE) is one of the most frequent causes of pleural effusion. The aims of the therapeutic management are palliation of symptoms and improvement in patient’s quality of life. The first step is a therapeutic thoracentesis. In case of a recurrent MPE, pleural maneuvers can be used to manage symptoms based on either ambulatory pleural drainage or pleurodesis to prevent fluid accumulation. The aim of this review is to describe recent advances, according to the best available evidence, in the field of pleurodesis for the management of MPE. Data source and study selection Three different searches of the most clinically relevant articles and up‐to‐date results in the field of pleurodesis for the management of MPE were performed using PubMed. Different indexing terms and time restriction were chosen. From these PubMed searches, 322 articles were respectively found. After cross‐checking these three lists and the selection of articles published after January 2010 specially dedicated to the management of MPE by pleurodesis, the abstracts of 106 articles were extracted to feed the corpus of this review. Results and conclusion Treatment approaches of recurrent MPE should take into account multiple factors in particular patient’s life expectancy and preference. If talc is the best sclerosing agent alone or in combination with indwelling pleural catheter which is a promising strategy, the pathophysiology of MPE has to be revisited in order to propose a personalized management targeting intrapleural key molecules involved in the genesis of malignant process.